147 related articles for article (PubMed ID: 10146934)
21. Health technology assessment in Australia: a role for clinical registries?
Scott AM
Aust Health Rev; 2017 Mar; 41(1):19-25. PubMed ID: 27028134
[TBL] [Abstract][Full Text] [Related]
22. Industry comment on the 1995 revised Australian pharmacoeconomic guidelines.
Grobler MP; Macarounas-Kirchmann K; Pearce GA; Stafford M
Pharmacoeconomics; 1996 Apr; 9(4):353-6. PubMed ID: 10160109
[No Abstract] [Full Text] [Related]
23. Health policy versus industrial policy in the pharmaceutical sector: the case of Canada.
Vandergrift M; Kanavos P
Health Policy; 1997 Sep; 41(3):241-60. PubMed ID: 10170092
[TBL] [Abstract][Full Text] [Related]
24. Pharmaceuticals in Australia: developments in regulation and governance.
Lofgren H; Boer Rd
Soc Sci Med; 2004 Jun; 58(12):2397-407. PubMed ID: 15081192
[TBL] [Abstract][Full Text] [Related]
25. HAS to be NICE?
de Pouvourville G
Eur J Health Econ; 2013 Jun; 14(3):363-6. PubMed ID: 23420083
[No Abstract] [Full Text] [Related]
26. Balancing health and industrial policy objectives in the pharmaceutical sector: lessons from Australia.
Morgan S; McMahon M; Greyson D
Health Policy; 2008 Aug; 87(2):133-45. PubMed ID: 18295927
[TBL] [Abstract][Full Text] [Related]
27. Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand.
Raftery JP
Med J Aust; 2008 Jan; 188(1):26-8. PubMed ID: 18205559
[TBL] [Abstract][Full Text] [Related]
28. Australian pharmaceutical policy: price control, equity, and drug innovation in Australia.
Doran E; Alexander Henry D
J Public Health Policy; 2008 Apr; 29(1):106-20. PubMed ID: 18368023
[TBL] [Abstract][Full Text] [Related]
29. The emerging government requirement for economic evaluation of pharmaceuticals.
Drummond M
Pharmacoeconomics; 1994; 6 Suppl 1():42-50. PubMed ID: 10155586
[TBL] [Abstract][Full Text] [Related]
30. Implications of the Australian guidelines for the United States.
Freund DA; Evans D; Henry D; Dittus R
Health Aff (Millwood); 1992; 11(4):202-6. PubMed ID: 1483641
[No Abstract] [Full Text] [Related]
31. Evidence-based decision-making in Asia-Pacific with rapidly changing health-care systems: Thailand, South Korea, and Taiwan.
Jirawattanapisal T; Kingkaew P; Lee TJ; Yang MC
Value Health; 2009; 12 Suppl 3():S4-11. PubMed ID: 20586980
[TBL] [Abstract][Full Text] [Related]
32. Government initiatives in the development of a pharmaceutical industry in Australia.
Hirst CA
Clin Exp Pharmacol Physiol; 1992 Jan; 19(1):57-61. PubMed ID: 1623637
[TBL] [Abstract][Full Text] [Related]
33. Pharmaceutical policies in Canada: another example of federal-provincial discord.
Anis AH
CMAJ; 2000 Feb; 162(4):523-6. PubMed ID: 10701389
[TBL] [Abstract][Full Text] [Related]
34. Assessing personalized medicines in Australia: a national framework for reviewing codependent technologies.
Merlin T; Farah C; Schubert C; Mitchell A; Hiller JE; Ryan P
Med Decis Making; 2013 Apr; 33(3):333-42. PubMed ID: 22895559
[TBL] [Abstract][Full Text] [Related]
35. Update and evaluation of Australian guidelines. Industry perspective.
Carmine B
Med Care; 1996 Dec; 34(12 Suppl):DS226-32. PubMed ID: 8969330
[No Abstract] [Full Text] [Related]
36. Funding arrangements for pharmaceuticals: can economic evaluation promote efficiency?
Viney R
Aust Health Rev; 2001; 24(2):21-4. PubMed ID: 11496466
[No Abstract] [Full Text] [Related]
37. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
Allen N; Walker SR; Liberti L; Salek S
Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
[TBL] [Abstract][Full Text] [Related]
38. Pharmaceutical research: cost savings through innovation.
Cohen KR; Levy RA
AAPPO J; 1993 Oct; 3(5):28-36. PubMed ID: 10146463
[No Abstract] [Full Text] [Related]
39. The reimbursement factor in pharmaceutical regulation: rebates, cost-effectiveness, and practice guidelines.
Shulman SR
Pharmacoeconomics; 1992; 1(Suppl 1):21-7. PubMed ID: 10146927
[TBL] [Abstract][Full Text] [Related]
40. Improving pharmaceutical innovation by building a more comprehensive database on drug development and use.
Daniel GW; Cazé A; Romine MH; Audibert C; Leff JS; McClellan MB
Health Aff (Millwood); 2015 Feb; 34(2):319-27. PubMed ID: 25646113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
